



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Attorney Docket No.: 102286.409CON)

Applicant(s): Jakobsen, et al.
Serial No.: 10/014,326
Filed: November 13, 2001
For: Soluble T Cell Receptor
Group Art Unit: 1642
Examiner: Minh-Tam Davis
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence is being as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date set forth below.

1/24/05


Name:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner:

Applicants and their attorney are aware of the following publications and information listed on the attached PTO Form 1449, and in accordance with 37 CFR §1.97(c)(2) hereby submit these documents for the Examiner's consideration. Copies of the cited U.S. patent references are not enclosed as the requirement under 37 CFR 1.98(a)(2)(i) has been waived.

Applicants reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application. If it should be determined that any of the listed documents constitute prior art under United States law, Applicants reserve the right to present to the Office relevant facts and law regarding the significance of such documents to the patentability of the claimed invention.

It is respectfully requested that the Examiner initial and return copies of the enclosed Form PTO-1449 with the next Patent Office communication.

01/28/2005 CCHAU1 0000042 080219 10014326


01 FC:1806 180.00 DA

U.S.S.N. 10/014,326
Jakobsen, et al.


This Information Disclosure Statement is being filed after receipt of a final Office Action and before the mailing date of a Notice of Allowance; therefore, the Commissioner is hereby authorize to charge the \$180.00 fee pursuant to 37 CFR §1.17(p) to Deposit Account No. 08-0219. The Commissioner is also authorized to charge any fee deficiency or credit any overpayment to Deposit Account No. 08-0219.

Respectfully submitted,

Date: Jan. 24, 2005


Michael J. Twomey
Registration No. 38,349
Attorney for Applicants

Wilmer Cutler Pickering Hale and Dorr LLP
60 State Street
Boston, Massachusetts 02109
Tel: (617) 526-6190
Fax: (617) 526-5000



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Attorney Docket No.: 102286.409CON)

Applicant(s): Jakobsen, et al.
Serial No.: 10/014,326
Filed: November 13, 2001
For: Soluble T Cell Receptor
Group Art Unit: 1642
Examiner: Minh-Tam Davis


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence is being as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date set forth below.

1/24/05

Date



Name:

TRANSMITTAL LETTER

Commissioner:

Enclosed for filing are the following documents:

- 1.) Supplemental Information Disclosure Statement;
- 2.) Form PTO-1449, including 35 documents; and
- 3.) Return Postcard.


Please charge any deficiency or credit any overpayment in connection with this matter to
Deposit account No. 08-0219.

Respectfully submitted,

Date: Jan. 24, 2005


Michael J. Twomey
Registration No. 38,349

Wilmer Cutler Pickering Hale and Dorr LLP
60 State Street
Boston, Massachusetts 02109
Tel: (617) 526-6190
Fax: (617) 526-5000




Supt. For, PTO-1449				Docket Number 102286.409 CON	Application Number 10/014,326
INFORMATION DISCLOSURE IN AN APPLICATION <i>(Use several sheets if necessary)</i>				Applicant Jakobsen, et al.	
Sheet	1	OF	3	Filing Date November 13, 2001	Group Art Unit 1642

U.S. Patent Documents				
Examiner Initial	Document Number	Publn. Date mm-dd-yyyy	Name Of Patentee Or Applicant Of Cited Documents	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
	5,328,985	07/12/1994	Takeshi	
	5,620,689	04/15/1997	Allen et al.	
	5,225,538	07/1993	Capon, et al.	
	09/723,716	11/28/00	Jakobsen, et al.	
	09/723,665	11/28/00	Jakobsen, et al.	
	09/335,087	6/17/99	Jakobsen, et al.	
	09/912,787	7/25/01	Jakobsen, et al.	
	09/334,969	6/17/99	Jakobsen, et al.	


Foreign Patent Documents					
Examiner Initial	Cite No.	Foreign Patent Document	Publn. Date mm-dd-yyyy	Country	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code-Number- Kind			

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	



Sub. For, PTO-1449				Docket Number 102286.409 CON	Application Number 10/014,326
INFORMATION DISCLOSURE IN AN APPLICATION <i>(Use several sheets if necessary)</i>				Applicant Jakobsen, et al.	
Sheet	2	OF	3	Filing Date November 13, 2001	Group Art Unit 1642

Examiner's Initial	Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)	
1	Ahmad et al., Cancer Research 52: 4817-4820 (1992)	
2	Ahmad et al., Cancer Research 53: 1484-1488 (1993)	
4	Allen, Drugs 54 Suppl 4: 8-14 (1997)	
5	Allen, Trends Pharmacol. Sci. 15: 215-220 (1994)	
6	Allen et al., Biochem. Soc. Trans. 23: 1073-1079 (1995)	
7	Allen et al., Biochim. Biophys. Acta. 1237: 99-108 (1995)	
8	Allen et al., Int. J. Cancer 62: 199-204 (1995)	
9	Altman et al., Science 274: 94-96 (1996)	
10	Bangham et al., J. Mol. Biol. 13: 238-252 (1965)	
11	Barenholz et al., FEBS Left 99: 210-214 (1979)	
12	Barker et al., J. Mol. Biol. 146: 451-467 (1981)	
13	Brunner et al. Biochim. Biophys. Acta. 455: 322-331 (1976)	
14	Callan et al., J. Exp. Med. 187: 1395-1402 (1998)	
15	Chen, et al., Pharm. Res. 13:1378-1383 (1996)	
16	Chen et al., Pharm Res. 14: 537-540 (1997)	
17	Cohen et al., Int. J. Technol. Assess Health Care 10: 121-130 (1994)	
18	Cohen et al., Proc Natl. Acad. Sci. USA 88: 10440-10444 (1991)	
19	Dunbar et al., Curr. Biol. 8: 413-416 (1998)	
20	Edelman et al., J. Pharm. Sci. 85: 1271-1275 (1996)	
21	Hansen et al., Biochim. Biophys. Acta 1239: 133-144 (1995)	
22	Huang, Biochemistry 8: 344-52 (1969)	
23	Konigsberg, et al., Biochim. Biophys. Acta., 1370: 243-251 (1998)	
24	Langer, Nature, 392: 5-10 (1998)	
25	Mayer et al., Biochim. Biophys. Acta 817: 193196 (1985)	
EXAMINER		DATE CONSIDERED
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.		



Subt. For, PTO-1449				Docket Number 102286.409 CON	Application Number 10/014,326
				Applicant Jakobsen, et al.	
Sheet	3	OF	3	Filing Date November 13, 2001	Group Art Unit 1642

	26	McHeyzer et al., Immunol. Rev. 150: 5-21 (1996)
	27	McMichael et al., J. Exp. Med. 187: 1367-1371 (1998)
	28	Murali-Krishna et al., Immunity 8: 177-187 (1998)
	29	Ogg et al., Science 279: 2103-2106 (1998)
	30	Okada et al., Pharm. Res. 12: 576-582 (1995)
	31	Szoka et al., Proc. Nat'l. Acad. Sci. USA, 75: 4194-4198 (1978)
	32	Tan et al., Ann. Acad. Med. Singapore, 19: 827-830 (1990)
	33	Uster et al., FEBS Left, 386: 243-246 (1996)
	34	Vessey et al., Eur J. Immunol., 27: 879-885 (1997)
	35	Zalipsky et al., J. Pharm. Sci. 85: 133-7 (1996)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	